Use of Depot Medroxyprogesterone Acetate and Fracture Risk | Zendy

Christian Meier | Zendy; Yolanda B. Brauchli | Zendy; Susan S. Jick | Zendy; Marius Kraenzlin | Zendy; Christoph Meier | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Use of Depot Medroxyprogesterone Acetate and Fracture Risk

Author(s) -

Christian Meier,

Yolanda B. Brauchli,

Susan S. Jick,

Marius Kraenzlin,

Christoph Meier

Publication year - 2010

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2010-0032

Subject(s) - medroxyprogesterone acetate , depot , medicine , context (archaeology) , medroxyprogesterone , bone mineral , gynecology , endocrinology , osteoporosis , estrogen , geography , archaeology

Depot medroxyprogesterone acetate (DMPA), which has a high rate of use among teenagers in Europe and the United States, has been associated with impaired bone mineral acquisition during adolescence and accelerated bone loss in later life. Studies on the association between DMPA use and fracture risk are limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research